Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Two-peptide repair stack · 1:1
Also known as Wolverine Blend
One vial, two repair peptides at equal load: BPC-157 and TB-500. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
One vial, two compounds at equal load: BPC-157 and TB-500. The pairing exists because the peptides work repair from different angles — BPC-157 on angiogenesis and the nitric-oxide axis, TB-500 (a thymosin β4 fragment) on actin binding and cell migration.
Set side by side, they let a single preparation probe both the vascular and the cytoskeletal sides of tissue response. That complementary mechanism is the reason the blend is handled as one unit rather than as two separate vials.
The published basis is each peptide on its own: BPC-157 across tendon, vascular, and gut-repair preparations; thymosin β4 / TB-500 across wound closure, epicardial mobilization, and venous-ulcer studies. The blend layer asks whether their angiogenic and cytoskeletal effects read additively in shared models.
Each peptide carries its own literature before they ever share a vial. BPC-157 reads through angiogenesis and connective-tissue models; TB-500, the thymosin β4 fragment, reads through actin regulation and cell migration. The blend is the place those two records overlap.
Studied together, the formulation lets a lab watch vascular and cytoskeletal responses in the same preparation instead of running them apart — the point of co-formulating rather than dosing two vials in parallel.
BPC-157 traces to gastric-peptide screening in the early 1990s. TB-500 comes from a separate line entirely — the thymosin β4 work on cytoskeletal dynamics and wound response.
Combining them was a research convenience: a single 1:1 preparation that brings both mechanistic stories into one controlled experiment.
Staresinic, M. et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
PubMedChang, C.H. et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 110(3):774–780.
PubMedSikiric, P. et al. (2012). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 19(1):126–132.
PubMedMalinda, K.M. et al. (1999). Thymosin beta4 accelerates wound healing.
PubMedSmart, N. et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.
PubMedGuarnera, G. et al. (2010). The effect of thymosin treatment of venous ulcers.
PubMedJanoshik Analytical measures identity, purity, and net content, lot by lot.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
